DK2516468T3 - ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE - Google Patents

ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE Download PDF

Info

Publication number
DK2516468T3
DK2516468T3 DK10798340.5T DK10798340T DK2516468T3 DK 2516468 T3 DK2516468 T3 DK 2516468T3 DK 10798340 T DK10798340 T DK 10798340T DK 2516468 T3 DK2516468 T3 DK 2516468T3
Authority
DK
Denmark
Prior art keywords
antibody
ser
antibodies
thr
val
Prior art date
Application number
DK10798340.5T
Other languages
Danish (da)
English (en)
Inventor
Hans-Jörg Bühring
Martin Hofmann
Steffen Aulwurm
Ludger Grosse-Hovest
Grundram Jung
Original Assignee
Synimmune Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synimmune Gmbh filed Critical Synimmune Gmbh
Application granted granted Critical
Publication of DK2516468T3 publication Critical patent/DK2516468T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10798340.5T 2009-12-23 2010-12-23 ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE DK2516468T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28952909P 2009-12-23 2009-12-23
PCT/EP2010/070659 WO2011076922A1 (en) 2009-12-23 2010-12-23 Anti-flt3 antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
DK2516468T3 true DK2516468T3 (en) 2016-05-23

Family

ID=43719470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10798340.5T DK2516468T3 (en) 2009-12-23 2010-12-23 ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE

Country Status (13)

Country Link
US (1) US9023996B2 (cg-RX-API-DMAC7.html)
EP (1) EP2516468B1 (cg-RX-API-DMAC7.html)
JP (1) JP5944831B2 (cg-RX-API-DMAC7.html)
CN (1) CN102770453B (cg-RX-API-DMAC7.html)
BR (1) BR112012015740B1 (cg-RX-API-DMAC7.html)
CA (1) CA2785178C (cg-RX-API-DMAC7.html)
DK (1) DK2516468T3 (cg-RX-API-DMAC7.html)
EA (1) EA027502B1 (cg-RX-API-DMAC7.html)
ES (1) ES2573642T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160422T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028629T2 (cg-RX-API-DMAC7.html)
SI (1) SI2516468T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011076922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859767C (en) * 2011-12-19 2018-09-11 Synimmune Gmbh Bispecific antibody molecule and use thereof for treatment of proliferative disease
CN104520321A (zh) * 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
WO2015001078A1 (en) * 2013-07-04 2015-01-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A new fusion protein to target and treat acute myloid leukemia cells
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CN104288765A (zh) * 2014-07-03 2015-01-21 成都中联生科基因科技有限公司 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
EA038349B1 (ru) * 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
UA122331C2 (uk) * 2015-03-09 2020-10-26 Едженсіс, Інк. Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
KR20180053744A (ko) * 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
CN116334143A (zh) 2015-11-23 2023-06-27 诺华股份有限公司 优化的慢病毒转移载体及其用途
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
IL296966A (en) * 2016-04-01 2022-12-01 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
EP3439699A4 (en) * 2016-04-04 2019-11-20 Hemogenyx LLC METHOD FOR ELIMINATING HEMATOPOETIC STEM CELLS / HEMATOPOIDIC PRECURSOR CELLS (HSC / HP) IN A PATIENT WITH BI-SPECIFIC ANTIBODIES
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN118063619A (zh) 2017-03-02 2024-05-24 诺华股份有限公司 工程化的异源二聚体蛋白质
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
CN119899277A (zh) 2017-06-02 2025-04-29 辉瑞公司 靶向flt3的嵌合抗原受体
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019028027A1 (en) * 2017-07-31 2019-02-07 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND FLT3
WO2019025484A1 (en) * 2017-08-01 2019-02-07 Julius-Maximilians-Universität Würzburg USE OF CAR-MODIFIED T LYMPHOCYTES FOR FLT3 AND FLT3 INHIBITORS FOR TREATING ACUTE MYELOID LEUKEMIA
SG11202003177RA (en) 2017-10-25 2020-05-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
KR20250008975A (ko) * 2018-01-26 2025-01-16 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP3768315A4 (en) * 2018-03-21 2022-11-30 Dana Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
KR102884943B1 (ko) * 2018-09-11 2025-11-12 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 개선된 항-flt3 항원 결합 단백질
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113544152B (zh) 2018-12-18 2024-10-15 勃林格殷格翰国际加拿大公司 Flt3激动剂抗体及其用途
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
CN115768463A (zh) * 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
JP7525109B2 (ja) * 2020-03-18 2024-07-30 学校法人金沢医科大学 Ｃｄ１３５＋細胞を含む医薬組成物
WO2021209495A1 (en) * 2020-04-14 2021-10-21 Symphogen A/S Anti-flt3 antibodies and compositions
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体（car）的细胞的组合疗法
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
IL310862A (en) * 2021-08-16 2024-04-01 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572374A (en) 1896-12-01 Rod-cutting apparatus
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2163345A1 (en) * 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US20020048772A1 (en) 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE19958134C2 (de) 1999-12-02 2003-05-15 Koenig & Bauer Ag Saugwalze
AU2001278898A1 (en) 2000-07-10 2002-01-21 Xencor Method for disigning protein libraries with altered immunogenicity
WO2002025588A2 (en) 2000-09-21 2002-03-28 Md Online Inc. Medical image processing systems
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
MXPA03011094A (es) 2001-05-31 2004-12-06 Medarex Inc Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
US20030130827A1 (en) 2001-08-10 2003-07-10 Joerg Bentzien Protein design automation for protein libraries
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20040008359A (ko) 2002-07-18 2004-01-31 삼성전자주식회사 계층적 움직임 벡터 탐색을 이용한 움직임 추정 방법 및장치 및 그를 적용한 동영상 부호화 시스템
EP2298805A3 (en) * 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1581904A2 (en) 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
JP2007521648A (ja) 2003-06-26 2007-08-02 アール．ジェイ． メアーズ エルエルシー バンド設計超格子を有するｍｏｓｆｅｔを有する半導体装置
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
EP1931709B1 (en) * 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007119796A1 (ja) * 2006-04-14 2007-10-25 Medical And Biological Laboratories Co., Ltd. エフェクター機能を有するポリペプチド変異体
JP2010525820A (ja) 2007-04-30 2010-07-29 セントコア・オーソ・バイオテツク・インコーポレーテツド 増強されたエフェクター機能を有する、抗組織因子抗体及び組成物
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
US9679104B2 (en) 2013-01-17 2017-06-13 Edico Genome, Corp. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
US9703321B2 (en) 2013-07-09 2017-07-11 I-Blades, Inc. Snap on wearable module
KR102185854B1 (ko) 2017-09-09 2020-12-02 애플 인크. 생체측정 인증의 구현

Also Published As

Publication number Publication date
HUE028629T2 (en) 2016-12-28
BR112012015740B1 (pt) 2020-09-29
SI2516468T1 (sl) 2016-06-30
US20120328612A1 (en) 2012-12-27
JP5944831B2 (ja) 2016-07-05
US9023996B2 (en) 2015-05-05
EP2516468A1 (en) 2012-10-31
EA201290370A1 (ru) 2013-04-30
BR112012015740A2 (pt) 2017-04-25
EA027502B1 (ru) 2017-08-31
CA2785178A1 (en) 2011-06-30
HRP20160422T1 (hr) 2016-05-20
CN102770453A (zh) 2012-11-07
ES2573642T3 (es) 2016-06-09
CN102770453B (zh) 2014-10-08
CA2785178C (en) 2019-09-03
JP2013515472A (ja) 2013-05-09
HK1172910A1 (zh) 2013-05-03
EP2516468B1 (en) 2016-03-02
WO2011076922A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DK2516468T3 (en) ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
AU2018282094B2 (en) Antibodies that specifically bind PD-1 and methods of use
AU2013262593B2 (en) ST2 antigen binding proteins
CN110382536B (zh) 抗pd-1抗体及其用途
US7557190B2 (en) Optimized proteins that target Ep-CAM
US20220372154A1 (en) Anti-tnfr2 antibodies and methods of use
EP4214240B1 (en) Anti-ccr8 antibodies
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN110709100A (zh) Trem2抗原结合蛋白及其用途
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20180054837A (ko) 인간 cd40에 특이적으로 결합하는 작용성 항체 및 사용 방법
TW201134488A (en) PD-1 antibodies
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
CN117545779B (zh) 抗ctla-4抗体的用途
KR20100057021A (ko) 신규한 항체
KR101817265B1 (ko) 혈청 아밀로이드 ｐ 성분에 특이적인 항원 결합 단백질
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
CN103328508A (zh) 针对制癌蛋白m(osm)的抗原结合蛋白
TW202229340A (zh) 多特異性抗體及抗體組合
US20240103010A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
KR20090114449A (ko) Ｉｇｆ-ⅰｒ에 대한 항체
HK1172910B (en) Anti-flt3 antibodies and methods of using the same
HK40100657B (en) Anti-ccr8 antibodies
HK40100657A (en) Anti-ccr8 antibodies
KR20150123811A (ko) 항-mcsp 항체